R21/Matrix-M™ Malaria Vaccine with Novavax’s Adjuvant Technology Receives WHO Recommendation

Sample article from our Health Care Sector

October 2, 2023 (press release) –

  • Strategic Advisory Group of Experts and Malaria Policy Advisory Group recommend use of R21/Matrix-M malaria vaccine in children to prevent malaria burden and disease in endemic areas
  • Recommendation is required for WHO prequalification designation

Today, the World Health Organization (WHO) announced its recommendation of the R21/Matrix-M™ malaria vaccine to prevent malaria in children following advice from its Strategic Advisory Group of Experts (SAGE) and Malaria Policy Advisory Group (MPAG). The vaccine contains R21 antigen developed by University of Oxford, specific to the malaria parasite, and Novavax’s Matrix-M, a saponin-based adjuvant that enhances the immune response, making it broader and more durable. The filing was submitted to the WHO by Oxford and the vaccine is being developed and manufactured by Serum Institute of India.

The recommendation is a required step on the pathway to the WHO’s prequalification (PQ) of the vaccine, which aims to ensure the safety and efficacy of vaccines through extensive inspection and assessment of data. PQ designation is necessary for United Nations agencies (e.g., UNICEF) and Gavi to procure the vaccine for eligible countries.

This is the first recommendation from WHO to support the use of a vaccine containing Novavax’s Matrix-M adjuvant in children as young as five months of age. It is based on a review of evidence that included results from a Phase 3 clinical trial conducted in four African countries with 4,800 children aged 36 months to five years. These results were shared in a manuscript that was posted on Preprints with the Lancet, and is in review for publication under the peer review process.

The R21/Matrix-M vaccine is one of several ongoing collaborations involving Novavax’s adjuvant technology, including additional research in malaria, tuberculosis and other infectious diseases in both humans and animals.

More information about the R21/Matrix-M malaria vaccine from University of Oxford may be found here.  

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

More from our Health Care Sector Coverage
See our dashboard in action - schedule an demo
Chelsey Quick
Chelsey Quick
- VP Client Success -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.